Evaluation of Von Willebrand Factor as a Marker For Early Diagnosis of Acute Respiratory Distress Syndrome (A.R.D.S) in Comparison to Interleukin 6 [IL-6]
In this prospective study of 60patients, we tested the hypothesis That markedly elevated levels of plasma von Willebrand factor (VWF) a marker of endothelial cell injury might predict the development of acute respiratory distress syndrome (A.R.D.S) in risky patients. We compared our result to IL.6 as control biomarker for A.R.D.S development.
Acute lung injury was quantified on two -point scoring system (Berlin definition of ARDS and Murray score of acute lung injury).
Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
研究概览
研究类型
注册 (预期的)
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Patients between 18 and 80 years old of both sexes.
- risk factor for development of acute respiratory distress syndrome or acute lung injury either by:
- Direct lung injury includes: Severe pneumonia (infection), Breathing a vomited stomach contents (aspiration), Breathing harmful fumes or smoke, severe trauma to the chest or other accident that bruises the lungs.
- Indirect lung injury includes: sepsis, Severe injury or trauma with shock, blood transfusions , drug overdose acute pancreatitis, fracture of the long bones, near drowning ,anaphylaxis, uremia, fat embolus , and intracranial insult.
Exclusion Criteria:
- (1) pregnancy;
- (2) a preexisting medical condition with a life expectancy less than 3 months
- (3) evidence of cardiogenic pulmonary edema
- (4) age under 18 years old or above 80 years old
- (5) late stages of liver cell failure, renal failure
- (6) severe myocardial infarction
- (7) deep coma.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
ARDS group ,
|
Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
其他名称:
|
non ARDS group
|
Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
level of vwf at 72 hours
大体时间:72 hours
|
Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
|
72 hours
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (预期的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
ARDS,人类的临床试验
-
National University Health System, Singapore主动,不招人
-
Southeast University, China完全的
-
Southeast University, ChinaFirst Affiliated Hospital of Wannan Medical College招聘中
VWF measurement的临床试验
-
Spanish Society of Thrombosis and HaemostasisFrancisco Vidal Pérez; Maria Fernanda López Fernández; Almudena Pérez Rodríguez; Irene Corrales... 和其他合作者未知
-
Ablynx, a Sanofi company完全的获得性血栓性血小板减少性紫癜美国, 奥地利, 比利时, 法国, 德国, 以色列, 意大利, 西班牙, 瑞士, 英国, 保加利亚, 罗马尼亚, 澳大利亚
-
Grifols Therapeutics LLCInstituto Grifols, S.A.招聘中
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Sintesi Research Srl未知